

Rana R Mckay

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/2673227/rana-r-mckay-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

105
papers

2,740
citations

25
h-index

51
g-index

124
ext. papers

3,743
ext. citations

5.5
avg, IF

4.67
L-index

#	Paper	IF	Citations
105	The renal clear cell carcinoma immune landscape.. <i>Neoplasia</i> , 2022 , 24, 145-154	6.4	0
104	Treatment Discontinuation in Patients With Muscle-Invasive Bladder Cancer Undergoing Chemoradiation.. <i>Advances in Radiation Oncology</i> , 2022 , 7, 100836	3.3	0
103	Biomarker-Based Phase II Study of Sapanisertib (TAK-228): An mTORC1/2 Inhibitor in Patients With Refractory Metastatic Renal Cell Carcinoma.. <i>JCO Precision Oncology</i> , 2022 , 6, e2100448	3.6	1
102	Real-World Effectiveness of Sipuleucel-T on Overall Survival in Men with Advanced Prostate Cancer Treated with Androgen Receptor-Targeting Agents.. <i>Advances in Therapy</i> , 2022 , 1	4.1	0
101	Impact of age on treatment response in men with prostate cancer treated with radiotherapy.. <i>BJUI Compass</i> , 2022 , 3, 243-250	0.9	0
100	Molecular profiling of advanced malignancies guides first-line N-of-1 treatments in the I-PREDICT treatment-naïve study. <i>Genome Medicine</i> , 2021 , 13, 155	14.4	8
99	Asymptomatic detection of SARS-CoV-2 among cancer patients receiving infusional anti-cancer therapy. <i>Cancer Medicine</i> , 2021 , 10, 8763	4.8	1
98	Development and initial clinical testing of a multiplexed circulating tumor cell assay in patients with clear cell renal cell carcinoma. <i>Molecular Oncology</i> , 2021 , 15, 2330-2344	7.9	4
97	Temporal Trends and Predictors in the Use of Stereotactic Body Radiotherapy for Treatment of Metastatic Renal Cell Carcinoma in the U.S. <i>Oncologist</i> , 2021 , 26, e905-e906	5.7	3
96	Tackling Diversity in Prostate Cancer Clinical Trials: A Report From the Diversity Working Group of the IRONMAN Registry. <i>JCO Global Oncology</i> , 2021 , 7, 495-505	3.7	3
95	Association of Health-Care System With Prostate Cancer-Specific Mortality in African American and Non-Hispanic White Men. <i>Journal of the National Cancer Institute</i> , 2021 , 113, 1343-1351	9.7	6
94	Comparison of germline mutations in African American and Caucasian men with metastatic prostate cancer. <i>Prostate</i> , 2021 , 81, 433-439	4.2	8
93	Germline alterations among Hispanic men with prostate cancer.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 10534-10534	2.2	0
92	Cardiovascular toxicities associated with abiraterone compared to enzalutamide-A pharmacovigilance study. <i>EClinicalMedicine</i> , 2021 , 36, 100887	11.3	2
91	Outcomes of Black men with prostate cancer treated with radiation therapy in the Veterans Health Administration. <i>Cancer</i> , 2021 , 127, 403-411	6.4	8
90	Results of a multicenter, phase 2 study of nivolumab and ipilimumab for patients with advanced rare genitourinary malignancies. <i>Cancer</i> , 2021 , 127, 840-849	6.4	14
89	Treatment of metastatic castration resistant prostate cancer with radium-223: a retrospective study at a US tertiary oncology center. <i>Prostate Cancer and Prostatic Diseases</i> , 2021 , 24, 210-219	6.2	2

88	ACE2 abrogates tumor resistance to VEGFR inhibitors suggesting angiotensin-(1-7) as a therapy for clear cell renal cell carcinoma. <i>Science Translational Medicine</i> , 2021 , 13,	17.5	8
87	Immune checkpoint inhibitors in advanced upper and lower tract urothelial carcinoma: a comparison of outcomes. <i>BJU International</i> , 2021 , 128, 196-205	5.6	3
86	Impact of concurrent ACE inhibitors and ARBs on outcomes with immune-checkpoint inhibitors (ICIs) for patients (pts) with metastatic renal cell carcinoma (mRCC).. <i>Journal of Clinical Oncology</i> , 2021 , 39, 354-354	2.2	
85	Next Steps: Sequencing Therapies in Metastatic Kidney Cancer in the Contemporary Era. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2021 , 41, 1-11	7.1	2
84	Outcomes for Muscle-invasive Bladder Cancer with Radical Cystectomy or Trimodal Therapy in US Veterans. <i>European Urology Open Science</i> , 2021 , 30, 1-10	0.9	2
83	PROMISE: a real-world clinical-genomic database to address knowledge gaps in prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2021 ,	6.2	3
82	Prospective Evaluation of Clinical Outcomes Using a Multiplex Liquid Biopsy Targeting Diverse Resistance Mechanisms in Metastatic Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2021 , 39, 2926-2937	2.2	10
81	Cabozantinib in Combination With Atezolizumab for Advanced Renal Cell Carcinoma: Results From the COSMIC-021 Study. <i>Journal of Clinical Oncology</i> , 2021 , 39, 3725-3736	2.2	13
80	Impact of Pathogenic Germline DNA Damage Repair alterations on Response to Intense Neoadjuvant Androgen Deprivation Therapy in High-risk Localized Prostate Cancer. <i>European Urology</i> , 2021 , 80, 295-303	10.2	6
79	Molecular features of exceptional response to neoadjuvant anti-androgen therapy in high-risk localized prostate cancer. <i>Cell Reports</i> , 2021 , 36, 109665	10.6	4
78	Response and Outcomes to Immune Checkpoint Inhibitors in Advanced Urothelial Cancer Based on Prior Intravesical Bacillus Calmette-Guerin.. <i>Clinical Genitourinary Cancer</i> , 2021 ,	3.3	1
77	Analysis of CDK12 alterations in a pan-cancer database.. <i>Cancer Medicine</i> , 2021 ,	4.8	1
76	The Impact of Age and Gender on Outcomes of Patients With Advanced Renal Cell Carcinoma Treated With Targeted Therapy. <i>Clinical Genitourinary Cancer</i> , 2020 , 18, e598-e609	3.3	4
75	Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. <i>Lancet, The</i> , 2020 , 395, 1907-1918	18.8	0
74	Testosterone therapy does not increase the risks of prostate cancer recurrence or death after definitive treatment for localized disease. <i>Prostate Cancer and Prostatic Diseases</i> , 2020 , 23, 689-695	6.2	4
73	Diversity of Enrollment in Prostate Cancer Clinical Trials: Current Status and Future Directions. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020 , 29, 1374-1380	4	27
72	Overall survival (OS) among Medicare beneficiaries receiving sipuleucel-T (sip-T) versus oral treatment for metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2020 , 38, 42-42	2.2	1
71	Outcomes of patients with pancreatic-only oligometastatic renal cell carcinoma (RCC).. <i>Journal of Clinical Oncology</i> , 2020 , 38, 681-681	2.2	0

70	Management of bone complications in patients with genitourinary malignancies. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020 , 38, 94-104	2.8	1
69	Results of a Multicenter Phase II Study of Atezolizumab and Bevacizumab for Patients With Metastatic Renal Cell Carcinoma With Variant Histology and/or Sarcomatoid Features. <i>Journal of Clinical Oncology</i> , 2020 , 38, 63-70	2.2	64
68	Improving research for prostate cancer survivorship: A statement from the Survivorship Research in Prostate Cancer (SuRECaP) working group. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020 , 38, 83-93	2.8	8
67	Clinical Outcomes of First-line Sunitinib Followed by Immuno-oncology Checkpoint Inhibitors in Patients With Metastatic Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2020 , 18, e350-e359	3.3	1
66	Practical Considerations and Challenges for Germline Genetic Testing in Patients With Prostate Cancer: Recommendations From the Germline Genetics Working Group of the PCCTC. <i>JCO Oncology Practice</i> , 2020 , 16, 811-819	2.3	16
65	A Retrospective Observational Analysis of Overall Survival with Sipuleucel-T in Medicare Beneficiaries Treated for Advanced Prostate Cancer. <i>Advances in Therapy</i> , 2020 , 37, 4910-4929	4.1	5
64	Immunotherapy for Localized Prostate Cancer: The Next Frontier?. <i>Urologic Clinics of North America</i> , 2020 , 47, 443-456	2.9	5
63	Optimized Management of Nivolumab and Ipilimumab in Advanced Renal Cell Carcinoma: A Response-Based Phase II Study (OMNIVORE). <i>Journal of Clinical Oncology</i> , 2020 , 38, 4240-4248	2.2	27
62	Effect of Antibiotic Use on Outcomes with Systemic Therapies in Metastatic Renal Cell Carcinoma. <i>European Urology Oncology</i> , 2020 , 3, 372-381	6.7	35
61	Systemic Treatment of Bone Disease in Metastatic Urinary Malignancies. <i>European Urology Focus</i> , 2020 , 6, 17-25	5.1	2
60	-Mutated Prostate Cancer: Clinical Outcomes With Standard Therapies and Immune Checkpoint Blockade. <i>JCO Precision Oncology</i> , 2020 , 4, 382-392	3.6	26
59	The Effect of Weight Change During Treatment With Targeted Therapy in Patients With Metastatic Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2019 , 17, 443-450.e1	3.3	3
58	Germline Genetic Testing in Advanced Prostate Cancer; Practices and Barriers: Survey Results from the Germline Genetics Working Group of the Prostate Cancer Clinical Trials Consortium. <i>Clinical Genitourinary Cancer</i> , 2019 , 17, 275-282.e1	3.3	22
57	Association of Treatment With 5 α -Reductase Inhibitors With Time to Diagnosis and Mortality in Prostate Cancer. <i>JAMA Internal Medicine</i> , 2019 , 179, 812-819	11.5	27
56	Rising Serum Uric Acid Level Is Negatively Associated with Survival in Renal Cell Carcinoma. <i>Cancers</i> , 2019 , 11,	6.6	4
55	Subcastrate Testosterone Nadir and Clinical Outcomes in Intermediate- or High-Risk Localized Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019 , 103, 1068-1076	4	4
54	Systemic therapy in the management of localized and locally advanced renal cell carcinoma: Current state and future perspectives. <i>International Journal of Urology</i> , 2019 , 26, 532-542	2.3	21
53	Association between Radical Prostatectomy and Survival in Men with Clinically Node-positive Prostate Cancer. <i>European Urology Oncology</i> , 2019 , 2, 584-588	6.7	4

52	Response of Primary Renal Cell Carcinoma to Systemic Therapy. <i>European Urology</i> , 2019 , 76, 852-860	10.2	4
51	Evaluating a Video-Based, Personalized Webpage in Genitourinary Oncology Clinical Trials: A Phase 2 Randomized Trial. <i>Journal of Medical Internet Research</i> , 2019 , 21, e12044	7.6	
50	Neoadjuvant Sunitinib Decreases Inferior Vena Caval Thrombus Size and Is Associated With Improved Oncologic Outcomes: A Multicenter Comparative Analysis. <i>Clinical Genitourinary Cancer</i> , 2019 , 17, e505-e512	3.3	11
49	Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study. <i>Lancet Oncology, The</i> , 2019 , 20, 581-590	21.7	81
48	Androgen deprivation therapy and depression in men with prostate cancer treated with definitive radiation therapy. <i>Cancer</i> , 2019 , 125, 1070-1080	6.4	8
47	Clinical implications of genetic aberrations in metastatic prostate cancer. <i>Current Opinion in Urology</i> , 2019 , 29, 319-325	2.8	
46	A phase 2 trial of abiraterone acetate without glucocorticoids for men with metastatic castration-resistant prostate cancer. <i>Cancer</i> , 2019 , 125, 524-532	6.4	5
45	Tumor cell heterogeneity and resistance; report from the 2018 Coffey-Holden Prostate Cancer Academy Meeting. <i>Prostate</i> , 2019 , 79, 244-258	4.2	10
44	Definitive Radiation Therapy and Survival in Clinically Node-Positive Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018 , 101, 1188-1193	4	12
43	Durable Clinical Benefit in Metastatic Renal Cell Carcinoma Patients Who Discontinue PD-1/PD-L1 Therapy for Immune-Related Adverse Events. <i>Cancer Immunology Research</i> , 2018 , 6, 402-408	12.5	42
42	Post prostatectomy outcomes of patients with high-risk prostate cancer treated with neoadjuvant androgen blockade. <i>Prostate Cancer and Prostatic Diseases</i> , 2018 , 21, 364-372	6.2	29
41	The Clinical Presentation, Survival Outcomes, and Management of Patients With Renal Cell Carcinoma and Cardiac Metastasis Without Inferior Vena Cava Involvement: Results From a Pooled Clinical Trial Database and Systematic Review of Reported Cases. <i>Clinical Genitourinary Cancer</i> , 2018 , 16, 227-233	3.3	7
40	Three-month posttreatment prostate-specific antigen level as a biomarker of treatment response in patients with intermediate-risk or high-risk prostate cancer treated with androgen deprivation therapy and radiotherapy. <i>Cancer</i> , 2018 , 124, 2939-2947	6.4	10
39	The Clinical Activity of PD-1/PD-L1 Inhibitors in Metastatic Non-Clear Cell Renal Cell Carcinoma. <i>Cancer Immunology Research</i> , 2018 , 6, 758-765	12.5	66
38	Neoadjuvant therapy for localized and locally advanced renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018 , 36, 31-37	2.8	33
37	Impact of Geographic Regions on Overall Survival in Patients With Metastatic Renal Cell Carcinoma: Results From an International Clinical Trials Database. <i>Journal of Global Oncology</i> , 2018 , 4, 1-14	2.6	2
36	Evolving Systemic Treatment Landscape for Patients With Advanced Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2018 , JCO2018790253	2.2	41
35	Radium-223 Dichloride in Combination with Vascular Endothelial Growth Factor-Targeting Therapy in Advanced Renal Cell Carcinoma with Bone Metastases. <i>Clinical Cancer Research</i> , 2018 , 24, 4081-4088	12.9	17

34	Comprehensive Genomic Profiling of Metastatic Tumors in a Phase 2 Biomarker Study of Everolimus in Advanced Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2018 , 16, 341-348	3.3	4
33	Comprehensive Analysis of Survival Outcomes in Non-Clear Cell Renal Cell Carcinoma Patients Treated in Clinical Trials. <i>Clinical Genitourinary Cancer</i> , 2017 , 15, 652-660.e1	3.3	21
32	Efficacy of Therapies After Galeterone in Patients With Castration-resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2017 , 15, 463-471	3.3	6
31	Genomic Resistance Patterns to Second-Generation Androgen Blockade in Paired Tumor Biopsies of Metastatic Castration-Resistant Prostate Cancer. <i>JCO Precision Oncology</i> , 2017 , 1,	3.6	8
30	Characterization of Patients With Poor-Risk Metastatic Renal-Cell Carcinoma: Results From a Pooled Clinical Trials Database. <i>Clinical Genitourinary Cancer</i> , 2017 ,	3.3	1
29	Proton Pump Inhibitors and Survival Outcomes in Patients With Metastatic Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2017 , 15, 724-732	3.3	24
28	Radium-223 Use in Clinical Practice and Variables Associated With Completion of Therapy. <i>Clinical Genitourinary Cancer</i> , 2017 , 15, e289-e298	3.3	30
27	Effect of Metformin Use on Survival Outcomes in Patients With Metastatic Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2017 , 15, 221-229	3.3	15
26	Statins and survival outcomes in patients with metastatic renal cell carcinoma. <i>European Journal of Cancer</i> , 2016 , 52, 155-62	7.5	29
25	Duration of Androgen Deprivation Therapy for High-Risk Prostate Cancer: Application of Randomized Trial Data in a Tertiary Referral Cancer Center. <i>Clinical Genitourinary Cancer</i> , 2016 , 14, e299-305	3.3	9
24	Risk factors and model for predicting toxicity-related treatment discontinuation in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. <i>Cancer</i> , 2016 , 122, 411-9	6.4	23
23	A phase 1 study of buparlisib and bevacizumab in patients with metastatic renal cell carcinoma progressing on vascular endothelial growth factor-targeted therapies. <i>Cancer</i> , 2016 , 122, 2389-98	6.4	9
22	Tumor control with PD-1 inhibition in a patient with concurrent metastatic melanoma and renal cell carcinoma 2016 , 4, 26		8
21	Body Mass Index and Metastatic Renal Cell Carcinoma: Clinical and Biological Correlations. <i>Journal of Clinical Oncology</i> , 2016 , 34, 3655-3663	2.2	111
20	Angiotensin system inhibitors and survival outcomes in patients with metastatic renal cell carcinoma. <i>Clinical Cancer Research</i> , 2015 , 21, 2471-9	12.9	88
19	Depth of remission is a prognostic factor for survival in patients with metastatic renal cell carcinoma. <i>European Urology</i> , 2015 , 67, 952-8	10.2	53
18	Diagnosis of Renal Cell Carcinoma: A Clinician's Perspective. <i>Surgical Pathology Clinics</i> , 2015 , 8, 657-62	3.9	7
17	The burden of skeletal-related events in patients with prostate cancer and bone metastasis. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015 , 33, 17.e9-17.e18	2.8	20

16	Phase 2 trial of sunitinib and gemcitabine in patients with sarcomatoid and/or poor-risk metastatic renal cell carcinoma. <i>Cancer</i> , 2015 , 121, 3435-43	6.4	53
15	Docetaxel, bevacizumab, and androgen deprivation therapy for biochemical disease recurrence after definitive local therapy for prostate cancer. <i>Cancer</i> , 2015 , 121, 2603-11	6.4	9
14	Programmed death ligand-1 expression in adrenocortical carcinoma: an exploratory biomarker study 2015 , 3, 3		63
13	Burden of hospital admissions and utilization of hospice care in metastatic prostate cancer patients. <i>Urology</i> , 2015 , 85, 343-9	1.6	14
12	A phase I study of buparlisib (BKM120) with bevacizumab (BEV) in patients (pts) with metastatic renal cell carcinoma (mRCC) progressing on prior vascular endothelial growth factor (VEGF) therapies.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 4559-4559	2.2	2
11	The impact of BMI on outcomes of patients with metastatic renal cell carcinoma treated with targeted therapy: An external validation data set and analysis of underlying biology from The Cancer Genome Atlas.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 405-405	2.2	1
10	A phase II trial of sunitinib and gemcitabine in sarcomatoid and/or poor-risk patients with metastatic renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 408-408	2.2	2
9	Impact of statins and survival outcomes in patients with metastatic renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 435-435	2.2	
8	Impact of bone and liver metastases on patients with renal cell carcinoma treated with targeted therapy. <i>European Urology</i> , 2014 , 65, 577-84	10.2	166
7	Mental health outcomes in elderly men with prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014 , 32, 1333-40	2.8	39
6	Adrenocortical carcinoma: the management of metastatic disease. <i>Critical Reviews in Oncology/Hematology</i> , 2014 , 92, 123-32	7	36
5	Dynamic contrast-enhanced magnetic resonance imaging in prostate cancer clinical trials: potential roles and possible pitfalls. <i>Translational Oncology</i> , 2014 , 7, 120-9	4.9	16
4	Optimizing bone health and minimizing skeletal morbidity in men with prostate cancer. <i>Hematology/Oncology Clinics of North America</i> , 2013 , 27, 1261-83, ix	3.1	4
3	Rationale for and review of neoadjuvant therapy prior to radical prostatectomy for patients with high-risk prostate cancer. <i>Drugs</i> , 2013 , 73, 1417-30	12.1	30
2	NCCN Task Force Report: Bone Health In Cancer Care. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2013 , 11 Suppl 3, S1-50; quiz S51	7.3	136
1	Prostate cancer 2012: where do we stand and where are we heading?. <i>Oncology</i> , 2012 , 26, 1222, 1224	1.8	1